AAV Vector manufacturing for diseases affecting very small populations (FOR-FD-21-007) is sponsored by Food and Drug Administration (FDA). This research aims to advance the development of gene therapies for diseases affecting very small populations by enhancing innovations in the manufacture of Adeno-associated virus (AAV) vectors.

AAV Vector manufacturing for diseases affecting very small populations | FOR FD 21 007 AAV Vector manufacturing for diseases affecting very small populations | FOR FD 21 007 Agriculture, Consumer Protection, Food and Nutrition Department of Health and Human Services, Food and Drug Administration Opportunity Information: Apply for FOR FD 21 007 This funding opportunity, titled "AAV Vector manufacturing for diseases affecting very small populations" (Funding Opportunity Number: FOR FD 21 007), is a discretionary grant program from the U.S. Department of Health and Human Services, Food and Drug Administration (FDA), specifically through the Center for Biologics Evaluation and Research (CBER).

The core purpose is to accelerate gene therapy development for diseases that affect extremely small patient groups, potentially down to a single individual, by improving how Adeno-associated virus (AAV) vectors are manufactured, tested, and evaluated.

Because AAV vectors are one of the most widely used delivery systems for in vivo gene therapy, CBER is aiming to push forward manufacturing approaches that can reliably produce small, patient-relevant batches while still meeting quality and regulatory expectations. A central theme of the program is enabling innovation that makes AAV vector production more efficient, more transparent, and less dependent on proprietary platforms.

The opportunity emphasizes practical, transferable advances that can be broadly implemented across the biologics industry and that also strengthen FDA regulatory science.

In other words, the work is expected to support the creation of science-based, risk-based regulatory approaches that help safe and effective gene therapies reach patients faster, especially when conventional commercial manufacturing models are unrealistic due to the tiny number of eligible patients. The scope of research highlighted by CBER includes several priority areas.

One major area is defining the critical quality attributes (CQAs) for AAV vectors used in gene therapy. CQAs are measurable properties that indicate whether a product is likely to be safe, potent, and consistent from batch to batch.

For AAV, this can involve attributes such as vector genome integrity, capsid content and composition, full-to-empty capsid ratios, potency and transduction efficiency, purity and residual impurities, and other characteristics that matter for performance and safety.

By improving clarity around what quality attributes truly drive clinical performance and risk, the field can move toward more consistent standards and more predictable regulatory review. Another key focus is the development of advanced analytics to increase process knowledge and strengthen manufacturing control.

This includes improved methods to measure CQAs more accurately, faster, and potentially in a way that supports in-process monitoring rather than relying only on final release testing. The goal is to better understand how upstream and downstream process steps influence product quality, and to build monitoring strategies that can detect issues early, support comparability assessments, and reduce the risk of failed batches.

For very small populations where each batch may represent a meaningful fraction of the total patient supply, process robustness and real-time insight become especially important. CBER also points to the development of a non-proprietary suite of AAV vectors suitable for gene therapy applications aimed at very small populations.

This reflects an intent to reduce barriers created by restricted access, licensing limitations, or closed manufacturing systems. A non-proprietary vector suite could help researchers and smaller developers avoid reinventing foundational tools and could make it easier to standardize methods and data across programs.

In practical terms, this could support wider adoption of common reference materials, shared characterization approaches, or broadly accessible vector constructs or capsids that are appropriate for rare and ultra-rare indications. A final emphasized area is demonstrating the feasibility of low-cost, non-proprietary Good Manufacturing Practice (GMP) manufacturing methods for AAV vectors at a scale appropriate for very small populations.

The opportunity explicitly frames the relevant scale as one batch yielding approximately 5 to 20 doses, which is far smaller than traditional commercial scales. This reflects the reality that for ultra-rare diseases, manufacturing needs to be economical and agile, without sacrificing GMP expectations for identity, purity, strength, quality, and safety.

The program is therefore oriented toward practical, end-to-end demonstrations that show how compliant manufacturing could be done in a way that is financially and operationally viable for tiny patient cohorts.

In terms of program structure and eligibility, the opportunity is open to a broad range of applicants, including state, county, and local governments; public and private institutions of higher education; nonprofit organizations (including both 501(c)(3) and non-501(c)(3) entities); tribal governments and tribal organizations; public housing authorities/Indian housing authorities; and for-profit organizations (including small businesses and other for-profit entities that are not small businesses).

The posted award ceiling is $600,000, with an anticipated five awards. The opportunity was created on May 25, 2021, and is listed under CFDA 93. 103.

While the funding activity category is listed as "Agriculture, Consumer Protection, Food and Nutrition," the substance of the announcement clearly centers on gene therapy manufacturing innovation and regulatory science within FDA/CBER.

Overall, the grant is best understood as an effort to modernize and democratize AAV vector manufacturing for situations where conventional development pathways are too slow, too expensive, or too industrially scaled to serve the needs of ultra-rare patients.

By investing in better-defined quality attributes, stronger analytics and process control, accessible non-proprietary vector options, and proven small-batch GMP methods, CBER is aiming not only to help therapies for very small populations move forward, but also to generate manufacturing and regulatory advances that can improve gene therapy development across the board.

The Department of Health and Human Services, Food and Drug Administration in the agriculture, consumer protection, food and nutrition sector is offering a public funding opportunity titled " AAV Vector manufacturing for diseases affecting very small populations " and is now available to receive applicants. Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93. 103 .

This funding opportunity was created on May 25, 2021. Applicants must submit their applications by Archiving forecast. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)

Each selected applicant is eligible to receive up to $600,000. 00 in funding. The number of recipients for this funding is limited to 5 candidate(s).

Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses.

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: Your browser does not support the video tag.

Browse more business programs for Manufacturing Companies Browse more opportunities from the same agency: Department of Health and Human Services, Food and Drug Administration Browse more opportunities from the same category: Agriculture, Consumer Protection, Food and Nutrition Next opportunity: Strengthening the healthcare system of Vietnam through capacity building, policy development and quality improvement of disease surveillance, laboratory and clinical services.

Previous opportunity: Cultural Resources On-Site Technical Support Hawaii Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Applicants also applied for: Applicants who have applied for this opportunity (FOR FD 21 007) also looked into and applied for these: Enhancing Innovations in Advanced Manufacturing Technologies for Vaccines against Influenza and Emerging Infectious Diseases Apply for FOR FD 21 006 Funding Number: FOR FD 21 006 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Renewal - Cooperative Agreement to Support the Joint Institute for Food Safety and Applied Nutrition, JIFSAN (U01) Clinical Trial Not Allowed Apply for RFA FD 22 004 Funding Number: RFA FD 22 004 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Funding Amount: $7,500,000 Conformance with the Egg Regulatory Program Standards (U2F) (Clinical Trial Not Allowed) Apply for RFA FD 22 006 Funding Number: RFA FD 22 006 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Funding Amount: $2,000,000 Research to support the development of alternatives to antimicrobials for use in food-producing animals Apply for PAR 22 087 Funding Number: PAR 22 087 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Innovative ways to provide education on antimicrobial stewardship practices in animals.

Apply for PAR 22 108 Funding Number: PAR 22 108 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Revision Applications - Development and Maintenance of the Animal Feed Regulatory Program Standards Flexible Funding Model Compliance and Enforcement Expansion Supplement (U18) (Clinical Trials Not Allowed) Apply for RFA FD 22 010 Funding Number: RFA FD 22 010 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Federal and State Integration Activities to Advance Cooperation and Regulatory Standards Among Animal Food Safety Regulatory Programs (U2F) Clinical Trials Not Allowed Apply for RFA FD 22 009 Funding Number: RFA FD 22 009 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Revision Applications - Manufactured Food Flexible Funding Model Compliance and Enforcement Expansion Supplement (U18) (Clinical Trials Not Allowed) Apply for RFA FD 22 019 Funding Number: RFA FD 22 019 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Retail Food Safety Regulatory Association Collaboration (U18) (Clinical Trial Not Allowed) Apply for RFA FD 22 008 Funding Number: RFA FD 22 008 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Funding Amount: $1,000,000 Renewal - Native American Tribes Outreach, Education, and Training to Enhance Food Safety and FSMA Compliance (U01) Clinical Trial Not Allowed Apply for RFA FD 22 025 Funding Number: RFA FD 22 025 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Renewal- Local Food Producer Outreach, Education, and Training to Enhance Food Safety and FDA Food Safety Modernization Act (FSMA) Compliance (U01) Clinical Trail Not Allowed Apply for RFA FD 22 024 Funding Number: RFA FD 22 024 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Funding Amount: $1,000,000 Funding Opportunity Title Innovation Award: Minority Health and Health Equity (U01) Clinical Trials Optional Apply for RFA FD 22 005 Funding Number: RFA FD 22 005 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition OMHHE Educational Funding Opportunity: Expanding education on skin lightening products (U01) Clinical Trials Optional Apply for RFA FD 22 020 Funding Number: RFA FD 22 020 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Building Research Capacity in Global Tobacco Product Regulation Program (U18) Clinical Trials Not Allowed Apply for RFA FD 23 003 Funding Number: RFA FD 23 003 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Cooperative Agreement to Support the Food and Agriculture Organization (FAO) (U01) Clinical Trials Not Allowed Apply for RFA FD 23 020 Funding Number: RFA FD 23 020 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Flexible Funding Model-Infrastructure Development and Maintenance for State Manufactured Food Regulatory Programs (U2F) Clinical Trials Not Allowed Apply for RFA FD 23 027 Funding Number: RFA FD 23 027 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Development and Maintenance of Human and Animal Food Rapid Response Teams (U2F) Clinical Trials Not Allowed Apply for RFA FD 23 019 Funding Number: RFA FD 23 019 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Renewal-Native American Tribes Outreach, Education, and Training to Enhance Food Safety and FSMA Compliance (U01) Clinical Trial Not Allowed Apply for RFA FD 23 032 Funding Number: RFA FD 23 032 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Renewal-Local Food Producer Outreach, Education and Training to Enhance Food Safety and FDA Food Safety Modernization Act (FSMA) Compliance (U01) Clinical Trial Not Allowed Apply for RFA FD 23 031 Funding Number: RFA FD 23 031 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Funding Amount: $1,000,000 Vet-LIRN Capacity-Building Project and Equipment Grants (U18) Apply for PAR 23 202 Funding Number: PAR 23 202 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Funding Amount: $2,500,000 Grant application guides and resources It is always free to apply for government grants.

However the process may be very complex depending on the funding opportunity you are applying for. Let us help you! Inside Our Applicants Portal Applicant Video Guides - The grant application process can be challenging to follow.

We can help you with intuitive video guides to speed up the process and eliminate errors in submissions. Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.

Premium leads for funding administrators, grant writers, and loan issuers Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience. Request more information: Would you like to learn more about this funding opportunity, similar opportunities to " FOR FD 21 007 ", eligibility, application service, and/or application tips? Submit an inquiry below: Request for More Information